Literature DB >> 27744447

Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial.

Hans M Nordahl1, Patrick A Vogel, Gunnar Morken, Tore C Stiles, Pål Sandvik, Adrian Wells.   

Abstract

BACKGROUND: The most efficacious treatments for social anxiety disorder (SAD) are the SSRIs and cognitive therapy (CT). Combined treatment is advocated for SAD but has not been evaluated in randomized trials using CT and SSRI. Our aim was to evaluate whether one treatment is more effective than the other and whether combined treatment is more effective than the single treatments.
METHODS: A total of 102 patients were randomly assigned to paroxetine, CT, the combination of CT and paroxetine, or pill placebo. The medication treatment lasted 26 weeks. Of the 102 patients, 54% fulfilled the criteria for an additional diagnosis of avoidant personality disorder. Outcomes were measured at posttreatment and 12-month follow-up assessments.
RESULTS: CT was superior to paroxetine alone and to pill placebo at the end of treatment, but it was not superior to the combination treatment. At the 12-month follow-up, the CT group maintained benefits and was significantly better than placebo and paroxetine alone, whereas there were no significant differences among combination treatment, paroxetine alone, and placebo. Recovery rates at 12 months were much higher in the CT group (68%) compared to 40% in the combination group, 24% in the paroxetine group, and 4% in the pill placebo group.
CONCLUSIONS: CT was the most effective treatment for SAD at both posttreatment and follow-up compared to paroxetine and better than combined treatment at the 12-month follow-up on the Liebowitz Social Anxiety Scale. Combined treatment provided no advantage over single treatments; rather there was less effect of the combined treatment compared to CT alone.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27744447     DOI: 10.1159/000447013

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  14 in total

Review 1.  Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials.

Authors:  Joseph K Carpenter; Leigh A Andrews; Sara M Witcraft; Mark B Powers; Jasper A J Smits; Stefan G Hofmann
Journal:  Depress Anxiety       Date:  2018-02-16       Impact factor: 6.505

Review 2.  A scoping review of the use of cannabidiol in psychiatric disorders.

Authors:  Anna E Kirkland; Matthew C Fadus; Staci A Gruber; Kevin M Gray; Timothy E Wilens; Lindsay M Squeglia
Journal:  Psychiatry Res       Date:  2021-12-20       Impact factor: 3.222

3.  Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis.

Authors:  Rachel Evans; David M Clark; Eleanor Leigh
Journal:  Behav Cogn Psychother       Date:  2020-12-10

Review 4.  Pharmacotherapy for social anxiety disorder (SAnD).

Authors:  Taryn Williams; Coenraad J Hattingh; Catherine M Kariuki; Sean A Tromp; Anton J van Balkom; Jonathan C Ipser; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2017-10-19

5.  Testing the metacognitive model against the benchmark CBT model of social anxiety disorder: Is it time to move beyond cognition?

Authors:  Henrik Nordahl; Adrian Wells
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

6.  Metacognitive Therapy for Social Anxiety Disorder: An A-B Replication Series Across Social Anxiety Subtypes.

Authors:  Henrik Nordahl; Adrian Wells
Journal:  Front Psychol       Date:  2018-04-12

Review 7.  Treating social anxiety disorder remotely with cognitive therapy.

Authors:  Emma Warnock-Parkes; Jennifer Wild; Graham R Thew; Alice Kerr; Nick Grey; Richard Stott; Anke Ehlers; David M Clark
Journal:  Cogn Behav Therap       Date:  2020-07-16

8.  Anterior cingulate cortex activity as a candidate biomarker for treatment selection in social anxiety disorder.

Authors:  Andreas Frick; Jonas Engman; Kurt Wahlstedt; Malin Gingnell; Mats Fredrikson; Tomas Furmark
Journal:  BJPsych Open       Date:  2018-05-11

9.  Antidepressant Use During Acute Inpatient Care Is Associated With an Increased Risk of Psychiatric Rehospitalisation Over a 12-Month Follow-Up After Discharge.

Authors:  Michael P Hengartner; Silvia Passalacqua; Andreas Andreae; Thomas Heinsius; Urs Hepp; Wulf Rössler; Agnes von Wyl
Journal:  Front Psychiatry       Date:  2019-02-22       Impact factor: 4.157

10.  Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders.

Authors:  Nobuo Masataka
Journal:  Front Psychol       Date:  2019-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.